Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data
Autor: | Jun Chen, Xiongfei Li, Song Xu, Yanye Wang, Ming Dong, Dian Ren, Gang Chen, Fan Ren, Zuoqing Song |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research Mutation rate Candidate gene Lung Neoplasms DNA Mutational Analysis Disease surgery 0302 clinical medicine Gene Frequency Carcinoma Non-Small-Cell Lung Medicine database Original Research Cancer Biology Middle Aged Prognosis early stage lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 030220 oncology & carcinogenesis Adenocarcinoma Female medicine.medical_specialty lcsh:RC254-282 03 medical and health sciences Internal medicine TP63 Biomarkers Tumor genomics Adjuvant therapy Humans Radiology Nuclear Medicine and imaging Lung cancer Alleles Aged Neoplasm Staging business.industry Proportional hazards model Genetic Variation medicine.disease Survival Analysis respiratory tract diseases lung cancer 030104 developmental biology Mutation Tumor Suppressor Protein p53 business |
Zdroj: | Cancer Medicine, Vol 9, Iss 20, Pp 7686-7694 (2020) Cancer Medicine |
ISSN: | 2045-7634 |
Popis: | Background The prognostic factors for early‐stage nonsmall cell lung cancers (NSCLCs) are not well defined. This study aimed to investigate the effect of highly frequent mutations on the outcomes patients with early‐stage NSCLC, particularly those with surgically resected stage I disease. Methods The Cancer Genome Atlas (TCGA) datasets for Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), and Pan‐Lung Cancer (PLC) were accessed via cBioportal and searched to identify patients with stage I NSCLC. We identified candidate genes with a high (>10%) frequency of mutations and copy‐number alterations and examined their effect on overall survival (OS) and disease‐free survival (DFS). The details of clinicopathologic features were analyzed with the Fisher's exact, Mann‐Whitney U test and Cox regression analysis. Survival was analyzed with Kaplan‐Meier curves, and differences were compared with the log‐rank and chi‐square test. Results We identified 408 patients with stage I NSCLC from the PLC dataset. Of the 41 candidate genes with high‐frequency mutation rates, six genes were significantly associated with OS: TP53, LPP, MAP3K13, FGF12, BCL6, and TP63. Further stratified analysis in PLC, LUAD, and LUSC datasets, we only identified that TP53 was significantly associated with OS in patients with surgically resected stage I lung adenocarcinoma. Conclusions TP53 mutations are potentially markers of poor prognosis for stage I lung adenocarcinoma patients. The mutation status of this gene may contribute to clinical decision‐making with respect to selecting patients who may benefit from adjuvant therapy. TP53 mutations are potentially markers of poor prognosis for stage I lung adenocarcinoma patients. The mutation status of this gene may contribute to clinical decision‐making with respect to selecting patients who may benefit from adjuvant therapy. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |